Author

A. Al-Shamkhani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. F. Vallejo· 1 shared A. L. Tutt· 1 shared A. W. E. Purcell· 1 shared B. Frendeus· 1 shared B. Mbiribindi· 1 shared C. H. Chan· 1 shared C. Penfold· 1 shared C. Retiere· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. F. Vallejo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Domain Binding and Isotype Dictate the Activity of Anti-human OX40 Antibodies

J. Griffiths, K. Hussain, H. L. Smith, T. Sanders, K. Cox, M. Semmrich, L. Martennson, J. Kim, T. Inzhelevskaya, C. Penfold, A. L. Tutt, I. Mockridge, C. H. Chan, V. English, R. R. French, , M. S. Cragg

This study evaluates how isotype and epitope of anti-human OX40 antibodies affect their therapeutic activity in tumor models.

bioRxiv · Jun 29, 2020Immunology

Peptide:MHC dependent activation of natural killer cells through KIR2DS2 generates anti-tumor responses

P. Rettman, M. D. Blunt, B. Mbiribindi, R. Fulton, R. Schittenhelm, A. F. Vallejo, L. Bastidas-Legarda, M. E. Polak, R. Ayala, A. W. E. Purcell, A. Al-Shamkhani, C. Retiere, S. I. Khakoo

This study shows that activating NK cells via KIR2DS2 with a peptide:MHC vaccine generates anti-tumor responses and identifies XPO1 as a cancer-associated ligand for KIR2DS2.

bioRxiv · Apr 15, 2020 · PreprintImmunology